Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

The clinical hold was placed on three studies investigating azenosertib in June after two patients died due to presumed ...

Mirvetuximab soravtansine was the first ADC to show efficacy as a therapy for platinum-resistant ovarian cancer. Despite high ...

While the FDA will take into consideration the committee’s vote, the vote is not binding upon the agency. The FDA will make the final decision and has assigned a Prescription Drug User Fee Act (PDUFA) ...

Data demonstrate broad activity of CBX-12 across six tumor types with a strong response rate in TOP1-naïve patients with ovarian (40%; N=10) and ...

According to the company, topline results will be presented at the 2024 American Academy of Ophthalmology Annual Meeting, ...

Experimental in vivo testing in-house and by its existing licensees has shown that ADCs built using Synaffix technology offer an improved therapeutic index over ADCs prepared from antibody–drug ...

The pioneering DNA testing firm has been struggling to stay afloat financially despite ambitious ventures to provide health ...

( MENAFN - Jordan Times) AMMAN - The Jordan Chamber of industry said that the industry index, recorded a growth of 1 per cent ...

Fintel reports that on September 19, 2024, UBS initiated coverage of Exelixis (NasdaqGS:EXEL) with a Neutral recommendation.